Amgen has placed its R&D and AI functions under a single executive, James Bradner, and appointed a new CTO — embedding AI governance directly into research leadership. The move signals a structural change in how large pharmaceutical companies are organizing themselves globally.
Across the industry, AI has moved from isolated pilot programs to organizational infrastructure. What once sat in separate technology departments is now fused into the core of research strategy at one of the world's largest drug developers.
At the AACR 2026 Annual Meeting, AI-native biotech Rakovina Therapeutics presented preclinical data from two generative AI-designed programs.1 The first targets dual ATR-mTOR inhibition — a combination approach long constrained by toxicity. The second focuses on CNS-penetrant oncology, engineering compounds to cross the blood-brain barrier.1
"Brain metastasis represents one of the most urgent and challenging frontiers in oncology," said Kazuko Matsuda.2 CNS penetrance failures have derailed oncology programs worldwide for years. Rakovina's platform is designed to engineer around that barrier directly.1
Revolution Medicines also presented preclinical data at AACR 2026 on RM-055, a mutant-targeted RAS inhibitor built for KRAS G12 mutations.3 In vivo, RM-055 suppressed RAS pathway activation in mutant tumors while sparing normal tissues — a selectivity profile that suggests a wider therapeutic window and room for combination regimens.3
Generative AI is targeting three failures that have limited oncology drug design globally: poor CNS penetrance, off-target toxicity, and weak mutant selectivity. These were the specific reasons earlier drug classes failed in patients from Tokyo to Toronto.
A crowded 2026 FDA regulatory calendar is sharpening investor attention on AI-designed pipelines, with multiple binary readouts expected across oncology programs in the near term.
When a company of Amgen's scale reorganizes its entire R&D hierarchy around AI leadership, the technology has crossed a threshold — from tool to strategy.
Sources:
1 Rakovina Therapeutics Inc., April 22, 2026, globenewswire.com
2 Kazuko Matsuda / MediciNova, Inc., April 27, 2026, globenewswire.com
3 Dr. Islam Mohamed, April 21, 2026, finance.yahoo.com
